Stephanie van Hoppe

62 Chapter 3 18. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component, J Clin Oncol, 12 (2017) 1288-1296. 10.1200/ JCO.2016.70.3223 19. Vishwanathan K, So K, Thomas K, et al. Absolute Bioavailability of Osimertinib in Healthy Adults, Clin Pharmacol Drug Dev, 2 (2019) 198-207. 10.1002/cpdd.467 20. Dickinson PA, Cantarini MV, Collier J, et al. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor, Drug Metab Dispos, 8 (2016) 1201-1212. 10.1124/dmd.115.069203 21. Planchard D, Brown KH, Kim DW, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies, Cancer Chemother Pharmacol, 4 (2016) 767-776. 10.1007/s00280-016-2992-z 22. Center for Drug valuation and Research of the U.S., Department of Health and Human Servics Food and Drug Administration., HIGHLIGHTS OF PRESCRIBING INFORMATION, (2017) 23. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs, J Clin Invest, 11 (1996) 2517-2524. 10.1172/JCI118699 24. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice, Adv Drug Deliv Rev, 1 (2009) 14-25. 10.1016/j.addr.2008.08.007 25. Yabuki N, Sakata K, Yamasaki T, et al. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance, Cancer Genet Cytogenet, 1 (2007) 1-9. 10.1016/j.cancergencyto.2006.07.020 26. Stuurman FE, Nuijen B, Beijnen JH, et al. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement, Clin Pharmacokinet, 6 (2013) 399-414. 10.1007/s40262-013-0040-2 27. Tang SC, Lagas JS, Lankheet NA, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration, International journal of cancer, 1 (2012) 223-233. 10.1002/ijc.26000 28. Tang SC, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar, International journal of cancer, 6 (2014) 1484-1494. 10.1002/ijc.28475 29. Kodaira H, Kusuhara H, Ushiki J, et al. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone, The Journal of pharmacology and experimental therapeutics, 3 (2010) 788-796. 10.1124/jpet.109.162321 30. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 1-2 (2012) 70-80. 10.1016/j.drup.2012.01.005 31. Lagas JS, van Waterschoot RA, van Tilburg VA, et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment, Clinical cancer research : an official journal of the American Association for Cancer Research, 7 (2009) 2344-2351. 10.1158/1078-0432.ccr-08-2253 32. Hsiao SH, Lu YJ, Li YQ, et al. Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance- Linked ATP-Binding Cassette Transporter ABCB1 in Vitro, Mol Pharm, 6 (2016) 2117-2125. 10.1021/acs. molpharmaceut.6b00249 33. Zhang XY, Zhang YK, Wang YJ, et al. Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells, Molecules, 9 (2016) 10.3390/molecules21091236 34. Chen Z, Chen Y, Xu M, et al. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo, Mol Cancer Ther, 8 (2016) 1845- 1858. 10.1158/1535-7163.MCT-15-0939 35. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions, Cancer treatment reviews, 8 (2014) 917-926. 10.1016/j.ctrv.2014.06.010 36. Visentin M, Biason P, Toffoli G. Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents, Pharmacology & therapeutics, 1 (2010) 82-90. 10.1016/j. pharmthera.2010.05.005